Spicka, I. Et Al. 2021. Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21 .

Spicka, I., Moreau, P., Martin, T., Facon, T., Martinez, G., Oriol, A., ... Koh, Y.(2021). Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21.

Spicka, Ivan Et Al. "Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21, 2021

Spicka, Ivan Et Al. "Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21, 2021

Spicka, I. Et Al. (2021) . "Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21.

@article{article, author={Ivan Spicka Et Al. }, title={Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2021}